PMID- 32858502
OWN - NLM
STAT- MEDLINE
DCOM- 20210218
LR  - 20210218
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 131
DP  - 2020 Nov
TI  - Emerging role of NRF2 in ROS-mediated tumor chemoresistance.
PG  - 110676
LID - S0753-3322(20)30869-6 [pii]
LID - 10.1016/j.biopha.2020.110676 [doi]
AB  - Chemoresistance is a central cause for the tumor management failure. Cancer cells 
      disrupt the redox homeostasis through reactive oxygen species (ROS) regulatory 
      mechanisms, leading to tumor progression and chemoresistance. The transcription 
      factor nuclear factor erythroid 2-related factor 2 (NRF2) is a master regulator 
      of neutralizing cellular ROS and restoring redox balance. Understanding the role 
      of NRF2 in ROS-mediated chemoresistance can be helpful in the development of 
      chemotherapy strategies with better efficiency. In this review, we sum up the 
      roles of ROS in the development of chemoresistance to classical chemotherapy 
      agents including cisplatin, 5-fluorouracil, gemcitabine, oxaliplatin, paclitaxel, 
      and doxorubicin, and how to overcome ROS-mediated tumor chemoresistance by 
      targeting NRF2. Finally, we propose that targeting NRF2 might be a promising 
      strategy to resist ROS-driven chemoresistance and acquire better efficacy in 
      cancer treatment.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Xue, Danfeng
AU  - Xue D
AD  - Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of 
      Nanchang University, Nanchang, 330006, Jiangxi, China.
FAU - Zhou, Xiongming
AU  - Zhou X
AD  - Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of 
      Nanchang University, Nanchang, 330006, Jiangxi, China.
FAU - Qiu, Jiaxuan
AU  - Qiu J
AD  - Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of 
      Nanchang University, Nanchang, 330006, Jiangxi, China. Electronic address: 
      qiujiaxuan@163.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200825
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Antineoplastic Agents)
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (NFE2L2 protein, human)
RN  - 0 (Reactive Oxygen Species)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Cell Death/drug effects/physiology
MH  - Drug Resistance, Neoplasm/drug effects/*physiology
MH  - Humans
MH  - NF-E2-Related Factor 2/*physiology
MH  - Neoplasms/drug therapy/*metabolism
MH  - Reactive Oxygen Species/*metabolism
OTO - NOTNLM
OT  - Chemoresistance
OT  - NRF2
OT  - Reactive oxygen species
EDAT- 2020/08/29 06:00
MHDA- 2021/02/20 06:00
CRDT- 2020/08/29 06:00
PHST- 2020/07/04 00:00 [received]
PHST- 2020/08/16 00:00 [revised]
PHST- 2020/08/20 00:00 [accepted]
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
PHST- 2020/08/29 06:00 [entrez]
AID - S0753-3322(20)30869-6 [pii]
AID - 10.1016/j.biopha.2020.110676 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2020 Nov;131:110676. doi: 10.1016/j.biopha.2020.110676. Epub 
      2020 Aug 25.